Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
about
Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis.Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosisTrabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma.Natural products synthesis: enabling tools to penetrate Nature's secrets of biogenesis and biomechanism.Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options.The efficacy of trabectedin in treating ovarian cancer.Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin.A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.Mathematical modeling of efficacy and safety for anticancer drugs clinical development.A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
P2860
Q30542069-3B2B871E-DF9B-49FC-9FD3-C9FC53D0081FQ34544598-4EB5DEB0-5F31-453F-A772-65EA4C3D4BFBQ34622323-F0B095DD-EA09-44A6-B42E-0ECA52ADD5C8Q35215703-D6300D57-1BB4-4394-8406-8F269C891FF4Q35898258-02D31CA2-E6AC-40CE-9EC8-3EC28829E396Q37760957-5D93CFE2-B6C7-4FFB-B1EC-E1ABF3230A0DQ38731757-473DB17D-0B7D-4E42-AF56-EE9288A2A0C4Q38763841-FDD90288-B473-4CA1-B135-BDAACAF2AE8EQ43737131-B7269E2A-9E5C-439A-9134-9CC6A69E1C58Q45243526-B0ABAC74-8E0C-4DD0-AC90-85C490FA0146Q46792354-877CF408-045D-420A-A3A6-65574063705DQ46866125-B9B3BEFD-FD1A-4AF9-A473-702A07E93A0AQ47663303-D5BFE2BB-4568-4D69-984F-17BB280DC0D8Q57570787-47424BE1-4F42-4833-B4D2-6EAECBFA5AEC
P2860
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Mechanism-based pharmacokineti ...... Yondelis) induced neutropenia.
@ast
Mechanism-based pharmacokineti ...... Yondelis) induced neutropenia.
@en
Mechanism-based pharmacokineti ...... Yondelis) induced neutropenia.
@nl
type
label
Mechanism-based pharmacokineti ...... Yondelis) induced neutropenia.
@ast
Mechanism-based pharmacokineti ...... Yondelis) induced neutropenia.
@en
Mechanism-based pharmacokineti ...... Yondelis) induced neutropenia.
@nl
prefLabel
Mechanism-based pharmacokineti ...... Yondelis) induced neutropenia.
@ast
Mechanism-based pharmacokineti ...... Yondelis) induced neutropenia.
@en
Mechanism-based pharmacokineti ...... Yondelis) induced neutropenia.
@nl
P2093
P2860
P356
P1476
Mechanism-based pharmacokineti ...... Yondelis) induced neutropenia
@en
P2093
A Soto-Matos
J J Perez-Ruixo
K Stuyckens
P Zannikos
P2860
P304
P356
10.1038/SJ.CLPT.6100259
P407
P577
2007-06-27T00:00:00Z